BIOLINERX LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.8 ILa | 0.00% |
|
-1.33% | -61.26% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -61.26% | 48.28M | - | ||
| +18.43% | 124B | B+ | ||
| +19.81% | 114B | B+ | ||
| -23.74% | 19.42B | B+ | ||
| -17.96% | 16.2B | A- | ||
| -19.97% | 15.31B | B | ||
| -49.33% | 14.19B | A- | ||
| +57.08% | 14.32B | C+ | ||
| +7.95% | 14.31B | C+ | ||
| +126.04% | 11.29B | C |
Investor Rating
Trading Rating
-
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
-
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
-
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-
Business Predictability
Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- BLRX Stock
- Ratings BioLineRx Ltd.
